ProCE Banner Activity

Myelofibrosis and Polycythemia Vera—Integrating Research Advances Into Clinical Practice: Expert Answers to Frequently Asked Questions, Edition 2

Text Module

In this activity, experts answer frequently asked questions from a live meeting series regarding the management of myelofibrosis and polycythemia vera, including clinical challenges in both diagnosis and treatment.

Released: June 07, 2018

Expiration: June 06, 2019

No longer available for credit.

Share

Faculty

Brady L. Stein

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Srdan Verstovsek

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Stephen Oh

Stephen Oh, MD, PhD

Associate Professor of Medicine
Co-Chief, Division of Hematology
Washington University School of Medicine
St Louis, Missouri

Nikolai Podoltsev

Nikolai Podoltsev, MD, PhD

Assistant Professor
Division of Hematology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Raajit K. Rampal

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Incyte

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with myelofibrosis or polycythemia vera.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Utilize clinical tools and evidence to help to distinguish PV and MF from reactive conditions 
  • Recognize the clinical impact of molecular mutations on diagnosis, prognosis, and treatment choices for patients with PV and MF
  • Analyze current and emerging clinical trial data of JAK1/2 inhibitors in PV and MF
  • Tailor therapy for patients with PV and MF, using evidence-based guidance on best practices, safety considerations, and new data 

Program Director Disclosure

Program Director

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Brady L. Stein, MD, MHS, has disclosed that he has received consulting fees from Incyte.

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Srdan Verstovsek, MD, PhD, has no real or apparent conflicts of interest to report.

Faculty Disclosure

Primary Author

Stephen Oh, MD, PhD

Associate Professor of Medicine
Co-Chief, Division of Hematology
Washington University School of Medicine
St Louis, Missouri

Stephen Oh, MD, PhD, has disclosed that he has received consulting fees from Incyte.

Nikolai Podoltsev, MD, PhD

Assistant Professor
Division of Hematology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Nikolai Podoltsev, MD, PhD, has no real or apparent conflicts of interest to report.

Raajit K. Rampal, MD, PhD

Associate Member
Director, MPN and Rare Hematologic Malignancies Program
Director, Center for Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
New York, New York

Raajit K. Rampal, MD, PhD, has disclosed that he has received consulting fees from Agios and Incyte and funds for research support from Constellation.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no real or apparent conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no real or apparent conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.

Additional Information

Program Medium

This program has been made available online.

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

Goal


The goal of this activity is to improve participants’ competence in and performance at treating patients with polycythemia vera or myelofibrosis.